Literature DB >> 10557093

The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.

Y Nagata1, T Anan, T Yoshida, T Mizukami, Y Taya, T Fujiwara, H Kato, H Saya, M Nakao.   

Abstract

Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability. To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome. The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover. Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent. First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization. Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation. These findings are evidence that mt p53 stabilization depends on the impaired ubiquitination due to both the loss of wt p53 function and the hsp90 association.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557093     DOI: 10.1038/sj.onc.1202978

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

2.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

Review 3.  The HSP90 chaperone machinery.

Authors:  Florian H Schopf; Maximilian M Biebl; Johannes Buchner
Journal:  Nat Rev Mol Cell Biol       Date:  2017-04-21       Impact factor: 94.444

Review 4.  Posttranslational phosphorylation of mutant p53 protein in tumor development.

Authors:  Manabu Matsumoto; Mutsuo Furihata; Yuji Ohtsuki
Journal:  Med Mol Morphol       Date:  2006-06       Impact factor: 2.309

Review 5.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

Review 6.  Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.

Authors:  Harvey Schwartz; Brad Scroggins; Abbey Zuehlke; Toshiki Kijima; Kristin Beebe; Alok Mishra; Len Neckers; Thomas Prince
Journal:  Cell Stress Chaperones       Date:  2015-06-13       Impact factor: 3.667

7.  Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase.

Authors:  Inbal Ipenberg; Noga Guttmann-Raviv; Hanan P Khoury; Ilana Kupershmit; Nabieh Ayoub
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

8.  The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.

Authors:  A Milano; F Perri; F Caponigro
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

9.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

Review 10.  The therapeutic target Hsp90 and cancer hallmarks.

Authors:  Yoshihiko Miyata; Hitoshi Nakamoto; Len Neckers
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.